Related Experiment Video
Updated: Oct 13, 2025

An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions
Published on: May 8, 2017
Anti-tuberculosis drug delivery for tuberculous bone defects
Long Hua1,2,3, Hu Qian1, Ting Lei1
1Department of Orthopedics, Xiangya Hospital Central South University, Hunan Engineering Research Center of Biomedical Metal and Ceramic Implants, Changsha, P. R. China.
Novel drug delivery systems using biological scaffolds loaded with anti-tuberculosis (TB) drugs offer a promising solution for treating tuberculous bone defects, overcoming limitations of traditional therapies and reducing recurrence.
Area of Science:
- Biomaterials Science
- Orthopedic Surgery
- Infectious Diseases
Background:
- Traditional treatments for tuberculous bone defects face challenges including systemic toxicity and disease recurrence.
- Tuberculosis (TB) affecting bones requires innovative therapeutic strategies for improved outcomes.
Purpose of the Study:
- To review and analyze biological scaffolds loaded with anti-TB drugs as a novel drug delivery strategy for tuberculous bone defects.
- To summarize existing drug-loading methods and identify limitations in current research.
Main Methods:
- Comprehensive literature review of studies published between September 1998 and September 2021.
- Analysis of various biological scaffolds and anti-TB drug-loading techniques.
- Classification of anti-TB drugs and their incorporation into scaffolds.
Main Results:
- Biological scaffolds loaded with anti-TB drugs demonstrate potential for enhanced treatment efficiency.
- Various drug-loading techniques can be employed to optimize drug delivery for bone defects.
- Identified limitations in existing research highlight areas for future development.
Conclusions:
- Drug-loaded scaffolds represent a promising approach for treating tuberculous bone defects.
- This strategy offers improved therapeutic efficacy and potential to mitigate TB recurrence.
- Further research is warranted to optimize scaffold design and drug-loading for clinical application.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Drug Distribution: Tissue Binding
For...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:

